Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsCash from RestructuringChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based Compensation
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Revenue - OtherShares OutstandingShares Outstanding
Ratios

Lyra Therapeutics (LYRA) Shares Issued (2019 - 2024)

Quarterly Shares Issued fell 25.0% to $3000.0 in Q1 2024 from the year-ago period, while the trailing twelve-month figure was $3000.0 through Dec 2024, down 97.09% year-over-year, with the annual reading at $3000.0 for FY2024, 97.09% down from the prior year.

Lyra Therapeutics' Shares Issued history spans 6 years, with the latest figure at $3000.0 for Q1 2024.

  • Shares Issued came in at $3000.0 for Q1 2024, up from $2000.0 in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $331000.0 in Q2 2021 to a low of -$59.9 million in Q4 2020.
  • The 5-year median for Shares Issued is $8000.0 (2022), against an average of -$6.6 million.
  • Year-over-year, Shares Issued tumbled 2994300.0% in 2020 and then fell 25.0% in 2024.
  • Lyra Therapeutics' Shares Issued stood at -$59.9 million in 2020, then soared by 100.02% to $11000.0 in 2021, then decreased by 27.27% to $8000.0 in 2022, then plummeted by 75.0% to $2000.0 in 2023, then skyrocketed by 50.0% to $3000.0 in 2024.
  • Per Business Quant, the three most recent readings for LYRA's Shares Issued are $3000.0 (Q1 2024), $2000.0 (Q3 2023), and $97000.0 (Q2 2023).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Shares Issued (Qtr)
1 Quantum Biopharma 1,384,976.65 Bn 1,384,976.64 Bn - 5.40 Mn
2 Alterity Therapeutics 777,208.84 Bn 777,208.81 Bn - -
3 Legend Biotech 2,801.00 Bn 2,800.10 Bn 242.10 Mn -
4 Nanobiotix 2,226.01 Bn 2,225.95 Bn - -
5 Akari Therapeutics 605.66 Bn 605.66 Bn - -
6 Vertex Pharmaceuticals 110.17 Bn 102.92 Bn 2.59 Bn 27.00 Mn
7 Regeneron Pharmaceuticals 66.86 Bn 58.11 Bn 3.31 Bn 163.10 Mn
8 Evaxion A 65.12 Bn 65.10 Bn - -
9 Alnylam Pharmaceuticals 39.94 Bn 36.94 Bn 959.66 Mn 13.16 Mn
10 Lyra Therapeutics - - - -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2024 3,000.00
Mar 31, 2024 3,000.00
Sep 30, 2023 2,000.00
Sep 30, 2023 2,000.00
Jun 30, 2023 97,000.00
Jun 30, 2023 97,000.00
Mar 31, 2023 4,000.00
Mar 31, 2023 4,000.00
Mar 31, 2022 8,000.00
Mar 31, 2022 8,000.00
Sep 30, 2021 11,000.00
Sep 30, 2021 11,000.00
Jun 30, 2021 331,000.00
Jun 30, 2021 331,000.00
Mar 31, 2021 262,000.00
Mar 31, 2021 262,000.00
Dec 31, 2020 -59.88 Mn
Dec 31, 2020 -59.88 Mn
Dec 31, 2019 2,000.00
Dec 31, 2019 2,000.00
Sep 30, 2019 22,000.00
Sep 30, 2019 22,000.00